VECTURA GROUP

 

VECTURA GROUP (VEC.L, LSE, LSE:VEC)

VEC Share PerformanceMore

52 week high182.00 28/05/15
52 week low113.25 16/10/14
52 week change 49.00 (37.40%)
4 week volume17,940,183 02/05/15

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Vectura widens FY pretax loss

Vectura Group has issued its preliminary results for the year ended 31 March 2015. It described the year as transformation...

Preliminary Results

RNS Number: 7122N Vectura Group plc 20 May 2015 Vectura Group plc - Preliminary Results Transformational Year - Maiden Profit Chippenham, UK - 20 May 2015: Vectura Group plc (LSE: VEC) ("Vectura"), which specialises in the development of products for the treatment of airways-related diseases , announces today its preliminary results for the year ended...

NOTIFICATION OF MAJOR INTEREST IN SHARES

RNS Number: 4834N Vectura Group plc 18 May 2015 For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Vectura Group PLC 2 Reason for the notification (please tick th...

Vectura to receive milestone payment

Vectura Group has confirmed that the information released today by The Medicines Company announcing that the U.S. F...

US FDA approval of RAPLIXA(TM) (fibrin sealant)

RNS Number: 0033M Vectura Group plc 01 May 2015 Vectura Group plc US FDA approval of RAPLIXA (fibrin sealant) Chippenham, UK - 1 May 2015: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), confirms the information released today by The Medicines Company (NASDAQ:MDCO) announcing that the U.S. Food and Drug Administration (FDA...

Voting Rights and Capital

RNS Number: 9242L Vectura Group plc 01 May 2015 Vectura Group plc (the "Company") VOTING RIGHTS AND CAPITAL Chippenham, UK, 1 May 2015: In accordance with the Financial Conduct Authority's Transparency Directive, Transitional Provision6, Vectura Group plc (LSE: VEC) ("the Company") wishes to notify the market of the following: The Compa...

Profit From The Biotech Boom With Vectura Group PLC, Hikma Pharmaceuticals Plc And Indivior PLC

After a record-breaking 2014, 2015 is shaping up to be another momentous year for biotech. During the first few months o...

Director Deals - (VEC)

Dr Christopher Blackwell, Chief Executive Officer, exercised 18,987 shares in the company on the 16th April 2015 at a price...